ASCOLT finds no overall adjuvant aspirin benefit in colorectal cancer, but meta-analysis links improved disease-free survival to PIK3CA exon 9/20 mutations.
|Articles|December 28, 2012
CMS to hospitals: Ready to report quality measures electronically?
Advertisement
he CMS wants to know whether hospitals will be able to begin submitting some previously established quality measures through their electronic health-record systems by 2014.
The agency published a
Read the full story:
Source: ModernHealthcare.com
Advertisement
Related to this article
IL-23 inhibitor risankizumab outperforms TYK2 inhibitor deucravacitinib for PASI 90 in biologic-naive moderate plaque psoriasis.
Dupilumab cut hand eczema severity (59.8% vs 15.2% with placebo), regardless of a patient's atopic history.
Christos Vaklavas, MD, discussed barriers limiting rural oncology access and challenges to adopting resource-intensive therapies.
FDA cut required monitoring for tarlatamab’s first 2 doses from 22-24 hours to 6-8 hours, easing a barrier to community cancer care.
Shiven B. Patel, MD, MBA, shares strategies for closing biomarker testing gaps, including among patients with non–small cell lung cancer.
The ESC's 2026 heart failure guidelines overhaul HF classification, rename therapy categories, and add a new HFpEF recommendation.
The FDA cleared PrecivityAD2, a blood test from C2N Diagnostics that helps diagnose Alzheimer disease in adults as young as 40.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
3
Aspirin's CRC Benefit Narrows to PIK3CA Exon 9/20 Mutations
4
Designing Effective Value-Based Oncology Models: Lalan Wilfong, MD
5